Presented in part at the 31st Annual Meeting of the Japanese Society for Apheresis held 4–6 November 2010 in Chiba, Japan.
Complete Early Virological Response Was Highly Achieved by Double Filtration Plasmapheresis Plus IFN-Beta Induction Therapy for HCV-1b Patients With Relapse or No Response After Previous IFN Therapy
Article first published online: 24 AUG 2011
© 2011 The Authors. Therapeutic Apheresis and Dialysis © 2011 International Society for Apheresis
Therapeutic Apheresis and Dialysis
Volume 15, Issue 4, pages 400–405, August 2011
How to Cite
Ishikawa, T., Higuchi, K., Kubota, T., Seki, K.-i., Honma, T., Yoshida, T., Kamimura, T., Tasaki, K., Hirose, S. and Suzuki, Y. (2011), Complete Early Virological Response Was Highly Achieved by Double Filtration Plasmapheresis Plus IFN-Beta Induction Therapy for HCV-1b Patients With Relapse or No Response After Previous IFN Therapy. Therapeutic Apheresis and Dialysis, 15: 400–405. doi: 10.1111/j.1744-9987.2011.00965.x
- Issue published online: 24 AUG 2011
- Article first published online: 24 AUG 2011
- Received December 2010; revised January 2011.
- Complete early virological response;
- Double filtration plasmapheresis;
- IFN-β induction;
- Virus removal and eradication by DFPP
The efficacy of double filtration plasmapheresis (DFPP) plus interferon (IFN)-β induction therapy was preliminarily investigated in re-treated patients with chronic genotype 1b hepatitis C and high viral load (patients with relapse or non-response to previous IFN therapies). In eight patients with chronic hepatitis C, DFPP was performed five times over 2 weeks during IFN-β therapy, and 3 MU of IFN-β was administered twice a day for 2 weeks. Combination therapies with ribavirin and pegylated IFN-α2b (PEG-IFN-α2b) or pegylated IFN-α2a (PEG-IFN-α2a) were subsequently used. After 4 weeks, hepatitis C virus (HCV)-RNA tended to be more greatly decreased with DFPP combination therapy than with previous IFN therapy (4.5 ± 2.0 log10IU/mL vs. 2.9 ± 1.2 log10IU/mL). Rates of both rapid virological response and complete early virological response were significantly higher with DFPP and IFN-β induction therapy than with previous IFN therapy. DFPP plus IFN-β induction therapy produced a great reduction of viral load during the early stage of treatment and achieved a high early virological response, suggesting that this combination therapy may be useful as a new treatment modality for chronic hepatitis C patients in difficult-to-treat states. This combination may contribute to sustained virological response (SVR). The effects of DFPP on SVR and its significance remain to be clarified.